Navigation Links
Taro Shareholders to Levitt and Directors: Quit the Board
Date:12/31/2009

ince 2003 and have permitted the Levitts unhindered use of Taro resources for their narrow personal gains.

Mr. Shanghvi continued, "It is time that the Levitts, who own a mere 12% of Taro's equity, hear the voice of the minority shareholders, in whose interest they claim to be working, and stop relying on their special founder shares to decide who will manage Taro. After watching Taro reach the brink of bankruptcy, seeing their shares delisted from trading, hearing endless false promises about receiving audited financial statements, and witnessing an unchecked drain of company resources, the shareholders have clearly had enough. A board of directors that cannot produce reliable audited financial statements for almost seven years simply should not remain in office."

The Levitt family has a signed contractual obligation to sell its shares to Sun at a pre-defined price. In line with this, Sun opted to buy the Levitt family shares in June 2008. However, the Levitts, with full support of the Taro directors, have prevented the close of this transaction through improper use of Taro resources. Taro directors initiated legal actions, at the company's expense, in order to protect the Levitt family from having to comply with its obligations. The Tel Aviv District Court ruled in favor of Sun in August 2008, and offered harsh criticism of the conduct of Taro's directors (the same directors who were re-elected and rewarded today by the Levitt family). Taro and its directors, under the pretext of protecting the same minority shareholders who have conclusively rejected them today, appealed to the Supreme Court, a decision that is awaited.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, specialty pharmaceutical company. It manufactur
'/>"/>

SOURCE Sun Pharmaceutical Industries Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CEL-SCI Corporation Releases Letter to Shareholders
2. Immtech Announces Posting of Annual Shareholders Meeting Presentation
3. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
4. CEL-SCI Corporation Releases Letter to Shareholders
5. Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
6. CEL-SCI Corporation Releases Letter to Shareholders
7. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
8. Letter to Shareholders From Imagenetix, Inc. President/CEO William Spencer
9. Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
10. CEL-SCI Corporation Releases Letter to Shareholders
11. Bob McDonald Outlines Key Long Term Growth Strategies To P&G Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has ... - Global Industry Analysis, Size, Share, Growth, Trends And ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... on patients in order to treat dental impairments, for ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... Radiologist Delivers Chemo Drug Directly to Eye via,Ophthalmic ... interventional,radiology treatment successfully treats advanced retinoblastoma -- a,deadly, ... children -- and often,spares them from having their ... a study released today at the Society of,Interventional ...
... Dependent on Outcomes of New Analyses or Confirmatory ... for Tuesday March 18, 2008, BERKELEY HEIGHTS, ... ) announced that the Food and Drug,Administration,s (FDA) ... that available data are not adequate to support ...
Cached Medicine Technology:New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 2New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 3New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 4FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 2FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 3FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 4FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 5FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 6
(Date:4/23/2014)... for-profit and non-profit organizations in Washington will receive ... Concept grants to accelerate maturation of promising health-related ... Sciences Discovery Fund (LSDF) announced today. Also announced ... the Washington Biotechnology & Biomedical Association (WBBA) to ... next generation of entrepreneurs and help early-stage companies ...
(Date:4/23/2014)... R.I. Parents and physicians concerned about an increase ... marijuana can breathe a sigh of relief. According to ... 20 years worth of data from states with and ... lead to increased use among adolescents. The study is ... Journal of Adolescent Health . , "Any time ...
(Date:4/23/2014)... The research, published in the journal Oncotarget ... have different appearances or their own DNA signatures ... it difficult to design effective, targeted treatment strategies. ... the EGFR mutation and either the KRAS or ... driven by the EGFR gene mutation have that ...
(Date:4/23/2014)... that proliferation of endogenous neural precursor cells cannot ... axons. From the perspective of neural plasticity, Dr. ... in China observed the effects of functional electrical ... and expression of basic fibroblast growth factor and ... the infarct side. The researchers found that functional ...
(Date:4/22/2014)... popular high school sport in the United States with ... researchers in the Center for Injury Research and Policy ... and describe the occurrence and distribution patterns of basketball-related ... athletic training setting among adolescents and teens. , The ... Training , examined data relating to adolescents 13-19 years ...
Breaking Medicine News(10 mins):Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3
... the nation,s largest builder of healthcare facilities, has ... hospital for Virtua Health. Turner is serving as ... scheduled for completion in 2011. The 690,000-sq.-ft. hospital ... quality clinical services and patient safety, an assurance ...
... 30 Diagnosoft, Inc., an innovator in magnetic ... diagnosis, staging and therapeutic monitoring of cardiovascular disease, ... Strain-encoding, or SENC, is a new MRI ... contraction, or relaxation, of the heart,s myocardium. ...
... Healthcare Management Group, Inc. (Phyhealth) (Pink Sheets: PHYH), ... in partnership with physicians and manager of Physhield ... released the following letter to its shareholders:Dear Phyhealth ... Congress and a new administration in Washington. ...
... Study says initiatives should target both coverage and access to ... Children who do not have health insurance and no regular ... unmet medical needs, researchers at the University of Michigan C.S. ... government needs to do more to safeguard the health of ...
... (Nasdaq: BCRX ) today announced that its fourth ... on Friday, February 6, 2009. Following the release, BioCryst will ... Eastern Time to discuss the financial results and provide an ... by Jon P. Stonehouse, President and Chief Executive Officer, Stuart ...
... Neurosilicon,s novel Photoconductive Stimulation Device (PSD) was highlighted in ... Astrocytic Ca2+ Waves Guide CNS Growth Cones to Remote ... November 2008 issue of The Public Library of Science ... in mediating axonal guidance. It is known that the ...
Cached Medicine News:Health News:Turner Reaches Milestone on $323 Million Virtua West Jersey Replacement Hospital in Voorhees, N.J. 2Health News:Diagnosoft(R) Introduces Its Third MRI Analysis Innovation 2Health News:Phyhealth Provides Update to Shareholders 2Health News:Phyhealth Provides Update to Shareholders 3Health News:Phyhealth Provides Update to Shareholders 4Health News:Medical Needs of 6.2 Million U.S. Kids Go Unmet 2Health News:BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009 2Health News:BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009 3Health News:Novel Photoconductive Cellular Depolarization Technology Reveals Insight Into Neuronal Growth, Guidance, and Regeneration 2
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Medicine POLYSORB Meniscal Stapler XLS consists of ... legs of the staple. The staple is ... the meniscus. The staple is made of ... lactic acid and glycolic acids. Polylactic/polyglycolic acid ...
Medicine Products: